Microbot Medical (MBOT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Nov, 2026Executive summary
Annual meeting scheduled for Dec. 14, 2026, at 9:00 a.m. ET; voting deadline is Dec. 13, 2026, at 11:59 p.m. ET.
Voting matters and shareholder proposals
Board recommends voting For Aileen Stockburger and Scott Burell as Class II directors, each to serve until the 2029 annual meeting.
Board recommends For a non-binding advisory resolution supporting named executive officer compensation.
Board recommends For an amendment to the 2020 Omnibus Performance Award Plan adding 1,000,000 authorized shares of common stock for issuance.
Board recommends For ratification of Brightman Almagor Zohar & Co. or its U.S. affiliate as independent registered public accounting firm for FY ending Dec. 31, 2026.
Shareholders may consider other business properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Two Class II seats are up for election; nominees are Aileen Stockburger and Scott Burell.
Latest events from Microbot Medical
- Four proposals seek director reelection, executive-pay support, plan shares, and auditor ratification.MBOT
Proxy filing - Revenue and customer base more than doubled as commercialization and regulatory milestones advanced.MBOT
Q2 2026 - LIBERTY’s disposable robotic system accelerates adoption in a vast, underserved market.MBOT
Oppenheimer 36th Annual Healthcare MedTech & Services Conference - Disposable robotic system gains traction in endovascular market, with broad expansion ahead.MBOT
38th Annual Roth Conference - LIBERTY's single-use robotic system drives rapid adoption in the large endovascular market.MBOT
25th Annual Needham Virtual Healthcare Conference - Pre-revenue surgical robotics firm registers shares for resale, dependent on LIBERTY® system success.MBOT
Registration filing - Annual meeting to vote on director elections, equity plan amendment, and auditor ratification.MBOT
Proxy filing - LIBERTY® robotic system developer registers shares for resale amid ongoing financial and regulatory risks.MBOT
Registration filing - Net loss rose to $11.4M in 2024; pivotal trials completed and $30M+ raised in early 2025.MBOT
Q4 2024